Journal of Skin and Stem Cell

Published by: Kowsar

Application of Allogeneic Fibroblast Cells in Cellular Therapy of Recessive Dystrophic Epidermolysis Bullosa

Sona Zare 1 , Reza Ahmadi 2 , Ayoob Rostamzadeh 3 , Soleiman Kurd 4 , Somayeh Hejazi 1 , Maryam Fard 5 , Maryam Anjomshoa 3 , ** and Mohammad Ali Nilforoushzadeh 1 , 6 , **
Authors Information
1 Skin and Stem Cell Research Center, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Clinical Biochemistry, Faculty of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
3 Department of Anatomical Sciences, Faculty of Medicine, Shahrekord University of Medical Sciences, Shahrekord, IR Iran
4 School of Advanced Technologies in Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
5 Department of Anatomical Science, Faculty of Medicine, Qazvin University of Medical Sciences, Qazvin, IR Iran
6 Skin Diseases and Leishmaniasis Research Center, Isfahan University of Medical Sciences, Isfahan, IR Iran
Corresponding Authors:
Article information
  • Journal of Skin and Stem Cell: September 1, 2015, 2 (3); e30787
  • Published Online: September 29, 2015
  • Article Type: Review Article
  • Received: June 15, 2015
  • Accepted: June 16, 2015
  • DOI: 10.17795/jssc30787

To Cite: Zare S, Ahmadi R, Rostamzadeh A, Kurd S, Hejazi S, et al. Application of Allogeneic Fibroblast Cells in Cellular Therapy of Recessive Dystrophic Epidermolysis Bullosa, J Skin Stem Cell. 2015 ; 2(3):e30787. doi: 10.17795/jssc30787.

Abstract
Copyright © 2015, Skin and Stem Cell Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Conclusions
Footnotes
References
  • 1. Liras A. Future research and therapeutic applications of human stem cells: general, regulatory, and bioethical aspects. J Transl Med. 2010; 8: 131[DOI][PubMed]
  • 2. Varki R, Sadowski S, Uitto J, Pfendner E. Epidermolysis bullosa. II. Type VII collagen mutations and phenotype-genotype correlations in the dystrophic subtypes. J Med Genet. 2007; 44(3): 181-92[DOI][PubMed]
  • 3. Kanitakis J. Anatomy, histology and immunohistochemistry of normal human skin. Eur J Dermatol. 2002; 12(4): 390-9[PubMed]
  • 4. Nystrom A, Velati D, Mittapalli VR, Fritsch A, Kern JS, Bruckner-Tuderman L. Collagen VII plays a dual role in wound healing. J Clin Invest. 2013; 123(8): 3498-509[DOI][PubMed]
  • 5. Fine J-D, Lanschützer C, Hintner H, Laimer M, Pohla-Gubo G, Nischler E, et al. Life with epidermolysis bullosa (EB): etiology, diagnosis, multidisciplinary care and therapy. 2009;
  • 6. Van Agtmael T, Bruckner-Tuderman L. Basement membranes and human disease. Cell Tissue Res. 2010; 339(1): 167-88[DOI][PubMed]
  • 7. Woodley DT, Krueger GG, Jorgensen CM, Fairley JA, Atha T, Huang Y, et al. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol. 2003; 121(5): 1021-8[DOI][PubMed]
  • 8. Chen M, Woodley DT. Fibroblasts as target cells for DEB gene therapy. J Invest Dermatol. 2006; 126(4): 708-10[DOI][PubMed]
  • 9. Hu R, Ling W, Xu W, Han D. Fibroblast-like cells differentiated from adipose-derived mesenchymal stem cells for vocal fold wound healing. PLoS One. 2014; 9(3)[DOI][PubMed]
  • 10. Chang HY, Chi JT, Dudoit S, Bondre C, van de Rijn M, Botstein D, et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A. 2002; 99(20): 12877-82[DOI][PubMed]
  • 11. Rodemann HP, Rennekampff H-O. Functional diversity of fibroblasts. Tumor-Associated Fibroblasts and their Matrix. 2011; : 23-36
  • 12. Gil KM, Wilson JJ, Edens JL, Webster DA, Abrams MA, Orringer E, et al. Effects of cognitive coping skills training on coping strategies and experimental pain sensitivity in African American adults with sickle cell disease. Health Psychol. 1996; 15(1): 3-10[PubMed]
  • 13. Pichler R, Klima G, Richter E, Marksteiner R, Mayr V, Skradski V, et al. Autologous fibroblast transplantation at the vesico-ureteral junction as potential reconstructive cell replacement in an animal model. World J Urol. 2013; 31(1): 169-74[DOI][PubMed]
  • 14. Yun YR, Won JE, Jeon E, Lee S, Kang W, Jo H, et al. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng. 2010; 2010: 218142[DOI][PubMed]
  • 15. Weiss RA. Autologous cell therapy: will it replace dermal fillers? Facial Plast Surg Clin North Am. 2013; 21(2): 299-304[DOI][PubMed]
  • 16. Kerstein MD. The scientific basis of healing. Adv Wound Care. 1997; 10(3): 30-6[PubMed]
  • 17. Smith SR, Munavalli G, Weiss R, Maslowski JM, Hennegan KP, Novak JM. A multicenter, double-blind, placebo-controlled trial of autologous fibroblast therapy for the treatment of nasolabial fold wrinkles. Dermatol Surg. 2012; 38(7 Pt 2): 1234-43[DOI][PubMed]
  • 18. Takeo M, Lee W, Ito M. Wound healing and skin regeneration. Cold Spring Harb Perspect Med. 2015; 5(1)[DOI][PubMed]
  • 19. Bello YM, Falabella AF, Eaglstein WH. Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol. 2001; 2(5): 305-13[PubMed]
  • 20. Restu Syamsul H, Indra K, Yurika S. Allogeneic human dermal fibroblasts are viable in peripheral blood mononuclear co-culture. Univ Med. 2014; 33: 91-9
  • 21. Auger FA, Lacroix D, Germain L. Skin substitutes and wound healing. Skin Pharmacol Physiol. 2009; 22(2): 94-102[DOI][PubMed]
  • 22. Thangapazham RL, Darling TN, Meyerle J. Alteration of skin properties with autologous dermal fibroblasts. Int J Mol Sci. 2014; 15(5): 8407-27[DOI][PubMed]
  • 23. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, et al. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2008; 128(9): 2179-89[DOI][PubMed]
  • 24. Snyder DL, Sullivan N, Schoelles KM. Skin Substitutes for Treating Chronic Wounds, Research conducted by the ECRI Institute Evidence-based Practice Center (EPC) under contract to the Agency for Healthcare Research and Quality (AHRQ). 2012;
  • 25. Horch RE, Kopp J, Kneser U, Beier J, Bach AD. Tissue engineering of cultured skin substitutes. J Cell Mol Med. 2005; 9(3): 592-608[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments